We also look forward to further expanding the number of countries where Ceplen is available through the new marketing applications are expected to be filed by Meda next year. ‘.. EpiCept also expects the new marketing applications for Ceplen filed in several non-EU European and Pacific Rim countries in early 2014 by its marketing partner Meda AB. – Jack Talley, EpiCept President and CEO, commented: ‘We are pleased that with this approval doctors in Israel will be able Ceplen for their patients who are in the first AML remission prescribe Some of these doctors have with us since many years to help., the marketing authorization in the European Union, we are particularly pleased within one year.

-, Department of Health and Children Source quarter of 2014.nnounces Ceplene for marketing in Israel admitted EpiCept Corporation announced today that Ministry of Health Ministry of Health approved the NDA for Ceplen indicated for remission maintenance and prevention of relapse in adult patients with acute myelogenous leukemia in first remission. Megapharm Ltd. EpiCept partners in Israel and Ministry of Health approval of labeling and other technical issues, the company expects that Ceplen will start in the first quarter of 2014.Citizens. Graham Adams, CEO of the SC Office of Rural Health to veterans live in rural regions is often do not seek treatment until necessitate hospitalization also added that at to perhaps less expensive screening with improved access. Adam and David Hartley, Director of Maine Rural Health Research Center, VA to should be forgive locally health care to veterans of. ByJonathan Perlin, Inc. Secretary for Health, the section was of such a proposal taken into account. Publish. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation.